HRT Financial
CRVS icon

HRT Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

HRT Financial’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-81,927
Closed -$260K – 2766
2025
Q1 		$260K Buy
81,927
+65,539
+400% +$309K ﹤0.01% 1853
2024
Q4 		$87K Buy
+16,388
New +$122K ﹤0.01% 2056
2023
Q4 		– Sell
-13,050
Closed -$19K – 2419
2023
Q3 		$19K Buy
+13,050
New +$27.6K ﹤0.01% 2075
2021
Q4 		– Sell
-30,769
Closed -$148K – 3321
2021
Q3 		$148K Buy
+30,769
New +$91.1K ﹤0.01% 2782

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's CRVS Position: Q2 2025 in Review

HRT Financial sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 81,927 shares — an estimated $260K sold.

HRT Financial first reported a position in CRVS in Q3 2021 and held it in 4 quarters. The position peaked at $260K in Q1 2025. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • HRT Financial reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 81,927 Corvus Pharmaceuticals shares in Q2 2025, an estimated $260K.
  • HRT Financial first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • HRT Financial's Corvus Pharmaceuticals position peaked at $260K in Q1 2025.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.